Latest News

Stay up to date with the latest stock market news from around the world. From breaking news written by our finance analysts to event-driven market news on a global scale.

TSE:3106
TSE:3106Luxury

Kurabo Industries (TSE:3106) One Off Gain Driven EPS Strength Challenges Earnings Quality Narratives

Kurabo Industries (TSE:3106) has put up another detailed scorecard for Q3 2026, with revenue of ¥36,001 million and basic EPS of ¥217.07, set against trailing twelve month EPS of ¥751.74 and net income of ¥12,558 million on revenue of ¥144,049 million. Over recent quarters the company has seen revenue move from ¥40,012 million in Q3 2025 to ¥38,803 million in Q4 2025, then to ¥35,744 million in Q1 2026 and ¥33,501 million in Q2 2026, while quarterly basic EPS has ranged from ¥173.06 in Q3...
NYSE:NUVB
NYSE:NUVBPharmaceuticals

A Look At Nuvation Bio’s Valuation As Safusidenib SIGMA Trial Advances To Phase 3

Nuvation Bio (NUVB) shares are in focus after the company advanced its SIGMA trial of safusidenib to Phase 3, expanding patient eligibility and enrollment in high risk IDH1-mutant glioma maintenance treatment. See our latest analysis for Nuvation Bio. The SIGMA trial update lands after a sharp 30 day share price return of around a 30% decline and a year to date share price return of a 34% decline, even though the 1 year total shareholder return is very large and the 3 year total shareholder...
TSE:7458
TSE:7458Entertainment

Daiichikosho Q3 2026 Margin Compression Reinforces Cautious Earnings Narratives

Daiichikosho (TSE:7458) has released its Q3 2026 results, reporting total revenue of ¥42,139 million and basic EPS of ¥34.12. The company’s quarterly revenue has moved from ¥37,435 million in Q2 2025 to ¥42,139 million in Q3 2026, while basic EPS has ranged between ¥58.61 and ¥25.12 over that period. This gives investors a clearer view of how revenue and EPS have behaved in recent quarters. With trailing 12 month EPS of ¥137.85 and a current share price of ¥1,712.5, the latest release puts a...
TSE:7203
TSE:7203Auto

Assessing Toyota Motor (TSE:7203) Valuation After Leadership Reshuffle And Updated Earnings Guidance

Toyota Motor (TSE:7203) has moved back into the spotlight after pairing a reshuffle at the top, with CFO Kenta Kon stepping up as CEO, with refreshed full year earnings guidance shaped by U.S. tariffs. See our latest analysis for Toyota Motor. The leadership reshuffle, updated guidance that factors in U.S. tariffs, and record global vehicle volumes have all come against a backdrop of firm share price momentum. A 30 day share price return of 9.62% and a 1 year total shareholder return of...
ENXTAM:MT
ENXTAM:MTMetals and Mining

ArcelorMittal Liberia Growth Deal Offsets Italian Legal Uncertainty

ArcelorMittal (ENXTAM:MT) has finalized a long term mining and infrastructure agreement with Liberia, covering iron ore production and exports. The deal includes plans for what is described as Africa’s largest iron ore beneficiation plant and an expansion of rail and port capacity to support higher shipment volumes. At the same time, ArcelorMittal faces a multibillion euro legal dispute in Italy over alleged misconduct and investment expropriation at Acciaierie d’Italia. The company denies...
NasdaqGS:PLAB
NasdaqGS:PLABSemiconductor

Is It Too Late To Consider Photronics (PLAB) After Its Strong Multi‑Year Share Price Run?

If you are wondering whether Photronics at US$37.54 is still reasonably priced after a strong run, you are not alone. The stock has returned 4.0% over the past week, 12.6% over the last 30 days, 12.4% year to date, 65.2% over 1 year, and 105.4% over 3 years, with a 5 year return of 182.9%. That naturally raises questions about what is already priced in and how much risk you are taking on at current levels. Recent attention on Photronics has focused on its position within the semiconductor...
TSE:2268
TSE:2268Hospitality

B-R 31 Ice CreamLtd (TSE:2268) Q4 Loss Tests Bullish Earnings Growth Narrative

Latest FY 2025 results set the stage for a margin focused read on B-R 31 Ice CreamLtd (TSE:2268) B-R 31 Ice CreamLtd (TSE:2268) has just wrapped up FY 2025 with Q4 revenue of ¥8,432 million and Basic EPS of ¥22.62 loss, capping a year in which trailing twelve month revenue reached ¥34,285 million and Basic EPS came in at ¥183.69. Over recent quarters the company has seen revenue move from ¥7,550 million in Q4 FY 2024 to ¥10,036 million in Q3 FY 2025, alongside EPS shifting from a ¥16.81 loss...
NasdaqGS:CRTO
NasdaqGS:CRTOMedia

Did Criteo’s New AI Commerce Engine Just Shift Its Retail Media Narrative (CRTO)?

Criteo recently launched its Agentic Commerce Recommendation Service, a commerce-grade AI engine that connects shopping assistants to merchants’ inventories using its commerce intelligence built on data from 720 million daily shoppers, US$1 trillion in annual transactions, and 4.50 billion product SKUs. The move signals Criteo’s push to sit at the center of AI-powered retail experiences, offering retailers and language model platforms a way to serve curated, transaction-ready product...
TSE:6507
TSE:6507Electrical

Sinfonia Technology (TSE:6507) Valuation Check After Solid Nine Month Earnings And Treasury Share Plans

Sinfonia TechnologyLtd (TSE:6507) has just reported nine month earnings to December 31, 2025, alongside a board meeting that includes an agenda item on disposing of treasury shares. This gives investors fresh financial and governance updates. See our latest analysis for Sinfonia TechnologyLtd. The latest earnings update and treasury share agenda come after a strong run in the stock, with a 17.30% 1 month share price return, 15.99% year to date share price return, and an 82.92% 1 year total...
TSE:3902
TSE:3902Healthcare Services

Medical Data Vision (TSE:3902) Return To Profit Challenges Concerns Over Core Earnings Power

Medical Data Vision (TSE:3902) has wrapped up FY 2025 with fourth quarter revenue of ¥1,888.8 million and basic EPS of ¥5.93, alongside trailing twelve month revenue of ¥6.5 billion and EPS of ¥7.40. Over recent quarters, the company has seen revenue move from ¥1,345.0 million and basic EPS of a ¥5.97 loss in the third quarter of FY 2024 to ¥1,888.8 million and EPS of ¥5.93 in the fourth quarter of FY 2025. Trailing twelve month net income has shifted from a ¥791.0 million loss to a ¥280.0...
TSE:7278
TSE:7278Auto Components

How Investors Are Reacting To EXEDY (TSE:7278) Upgraded FY2026 Guidance And Governance Shift

EXEDY Corporation recently raised its consolidated earnings guidance for the fiscal year ending March 31, 2026, citing a weaker yen and stronger-than-expected third-quarter results, and reported nine‑month net sales of ¥226,448 million and net income of ¥11,089 million. The company also announced that its board is considering a transition to a company with a nominating committee, signaling a potential shift in governance structure alongside improving earnings per share. Next, we will...
TSE:8544
TSE:8544Banks

Keiyo Bank (TSE:8544) Margin Compression To 15.1% Tests Bullish Valuation Narratives

Keiyo Bank (TSE:8544) has posted its Q3 2026 numbers with revenue of ¥26,999 million and basic EPS of ¥28.77, giving investors a fresh read on how its income statement is holding up. Over the past few quarters, revenue has moved from ¥17,094 million in Q4 2025 to ¥19,979 million in Q1 2026, ¥23,428 million in Q2 2026 and now ¥26,999 million. Basic EPS over the same stretch has gone from ¥4.61 to ¥33.93, ¥41.66 and then ¥28.77. With trailing net profit margins easing from 19.9% to 15.1%, this...
ASX:PME
ASX:PMEHealthcare Services

A Look At Pro Medicus’s Valuation As AI Jitters Pressure Tech Stocks And Create A Possible Opening

Recent volatility in technology stocks, driven by concerns about the impact of AI on valuations, has pushed Pro Medicus (ASX:PME) sharply lower and prompted some investors to reassess the medical imaging specialist. See our latest analysis for Pro Medicus. Those AI related worries have come on top of already weak momentum, with a 30 day share price return of 20.24% and a 90 day share price return of 34.82%. The 1 year total shareholder return of 42.43% contrasts with a very large 3 year total...
TSE:6845
TSE:6845Electronic

Assessing Azbil (TSE:6845) Valuation After Softer Nine-Month Earnings Results

Earnings-driven reset for Azbil (TSE:6845) Azbil (TSE:6845) has drawn fresh attention after reporting nine month results to December 31, 2025, with sales of ¥208,055 million and net income of ¥22,678 million, both below the prior year period. See our latest analysis for Azbil. Azbil’s latest earnings update arrived after a period of weaker momentum in the share price, with a 30 day share price return of 10.75% and a 90 day return of 15.85%. Even so, the 3 year total shareholder return sits at...
NYSE:MRK
NYSE:MRKPharmaceuticals

Merck Broadens Growth Drivers With Women’s Health And Infant RSV Moves

Merck (NYSE:MRK) has entered a collaboration with Calla Lily Clinical Care to develop a novel intravaginal drug delivery platform using the Callavid device. Health Canada has approved Merck’s ENFLONSIA (clesrovimab), an RSV prevention therapy for infants, expanding the company’s reach in pediatric respiratory care. For investors watching Merck’s mix of businesses, these developments sit outside the company’s oncology focus and add more weight to its broader pharmaceutical portfolio. The...
TSE:5805
TSE:5805Electrical

SWCC (TSE:5805) Margin Improvement Supports Bullish Narratives Despite Premium P/E

SWCC (TSE:5805) just posted its Q3 2026 scorecard, reporting revenue of ¥73.2b and basic EPS of ¥184.09, supported by a trailing twelve month EPS of ¥554.51 on revenue of ¥261.7b. The company’s quarterly revenue increased from ¥59.6b in Q4 2025 to ¥73.2b in Q3 2026, while basic EPS rose from ¥123.51 to ¥184.09 over the same period, supported by trailing twelve month net income of ¥16.4b. For investors, an important focus is how this earnings power is reflected in margins and what that implies...
NYSE:KRC
NYSE:KRCOffice REITs

Kilroy Realty Impairment Weighs On Earnings But Shares Screen As Undervalued

Kilroy Realty (NYSE:KRC) recorded a significant real estate asset impairment in its latest quarterly results. The impairment reduced the reported value of certain properties and contributed to a sharp year over year drop in quarterly net income. This represents a material shift in how the company’s asset base and recent earnings may appear to investors. Kilroy Realty enters this update with shares at $34.54 and a mixed recent track record. The stock is up 1.1% over the past week, but shows...
OM:NYF
OM:NYFReal Estate

Nyfosa (OM:NYF) Premium P/E Tests Bullish Narrative After Sharp EPS Rebound

Nyfosa (OM:NYF) closed out FY 2025 with Q4 revenue of SEK 905 million and EPS of SEK 0.89. On a trailing twelve month basis, EPS came in at SEK 2.45 and revenue at SEK 3.59 billion, setting the backdrop for a year where reported earnings swung sharply. Over recent quarters the company has seen quarterly revenue move in a tight band between SEK 884 million and SEK 925 million, with EPS ranging from a loss of SEK 0.33 in Q2 2025 to SEK 1.38 in Q3 2025. The trailing net profit margin currently...
TSE:7966
TSE:7966Chemicals

Lintec (TSE:7966) Margin Compression After ¥7.8b One Off Loss Tests Bullish Narratives

LINTEC (TSE:7966) has released its Q3 2026 results, reporting revenue of ¥82.1b and basic EPS of ¥77.43, while the trailing twelve-month figures show revenue of ¥313.8b and EPS of ¥185.84 as investors weigh those numbers against the impact of earlier one-off items. Over recent quarters the company has reported revenue between ¥76.1b and ¥82.4b per quarter and basic EPS between ¥57.56 and ¥78.06, giving a clear view of how the top line and per share earnings have led into this latest update...
TSE:9616
TSE:9616Hospitality

Kyoritsu Maintenance Q3 Margin Compression Tests Bullish Growth Narratives

Kyoritsu Maintenance (TSE:9616) has put another solid quarter on the board, with Q3 2026 revenue at ¥63,011 million and net income at ¥5,525 million, translating to basic EPS of ¥63.42. The company has seen revenue move from ¥59,090 million in Q3 2025 to ¥63,011 million in Q3 2026, while EPS shifted from ¥64.38 to ¥63.42 over the same period, providing a clear view of how the top line and earnings are tracking. With a trailing net profit margin of 6.7% versus 7.7% last year, this set of...
TSE:7481
TSE:7481Consumer Retailing

Oie Sangyo (TSE:7481) Margin Slippage To 2.2% Tests Bullish Valuation Narrative

Oie Sangyo (TSE:7481) has put up another solid quarter, with Q3 2026 revenue of ¥34.4b and basic EPS of ¥79.52, set against trailing twelve month revenue of ¥127.2b and EPS of ¥339.57 that reflects 8.5% revenue growth over the past year. The company has seen revenue move from ¥111.4b to ¥127.2b on a trailing basis, while quarterly EPS has ranged between ¥66.61 and ¥89.93 over the past six quarters, providing a clear view of how top line scale and per share earnings have been tracking...
NYSE:FDP
NYSE:FDPFood

Fresh Del Monte Produce (FDP) Valuation Check After Recent Share Price Momentum

Why Fresh Del Monte Produce (FDP) Is On Investors’ Radar Fresh Del Monte Produce (FDP) has caught investor attention after a period where its shares show mixed short term moves but stronger longer term total returns, inviting a closer look at how the business is currently positioned. See our latest analysis for Fresh Del Monte Produce. At a share price of $38.26, Fresh Del Monte Produce has seen a 6.25% 1 month share price return and an 8.32% year to date share price return, while its 1 year...
TSE:4072
TSE:4072IT

Densan System Holdings (TSE:4072) Earnings Growth Of 56.5% Reinforces Bullish Community Narratives

Densan System Holdings (TSE:4072) has put fresh numbers on the table for FY 2025, with Q4 revenue of ¥17.951 billion and net income of ¥661 million translating into basic EPS of ¥61.75, framed by trailing 12 month revenue of ¥68.131 billion and EPS of ¥270.97. Over recent quarters, revenue has moved from ¥14.863 billion in Q3 FY 2024 to ¥17.951 billion in Q4 FY 2025, while quarterly EPS has ranged from a loss of ¥22.45 in Q3 FY 2024 to ¥94.10 in Q4 FY 2024 and then ¥61.75 in the latest...
NasdaqGS:BBIO
NasdaqGS:BBIOBiotechs

A Look At BridgeBio Pharma (BBIO) Valuation After Earnings Uncertainty Triggers A Sharp Share Price Decline

Market reaction to earnings uncertainty BridgeBio Pharma (BBIO) dropped 15.24% on Thursday as investors reacted to growing uncertainty around its upcoming fourth quarter and full year 2025 results, expected on February 19, 2026. The move came even as Barclays and Morgan Stanley maintained favorable views on the stock, highlighting a difference between cautious market sentiment and more optimistic analyst commentary ahead of the earnings release. See our latest analysis for BridgeBio...